Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

• Market Cap: ₹5.51B
• Dividend Yield: N/A
• Average Volume (3M): 2.19K
• Price to Earnings (P/E): 34.5
• Beta (1Y): 1.06
• Revenue Growth: 32.95%
• EPS Growth: 67.39%
• Country: IN
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.54
• Shares Outstanding: 17,480,782
• 10 Day Avg. Volume: 2,304
• 30 Day Avg. Volume: 2,185
• PEG Ratio: 0.27
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 2.92
• P/FCF Ratio: -19.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 14.5
• Revenue Forecast (FY): ₹2.24B

• Rating: 57 Neutral
• Price Target: ₹326.00 ▼(-8.32% Downside)
• Action: Reiterated Date: 11/15/25
• Date: Action: Reiterated 11/15/25

Kilitch Drugs' overall stock score is driven by its strong financial performance, despite challenges in operational efficiency and cash flow management. Technical indicators suggest bearish momentum, which weighs on the score. The valuation is moderate, but the lack of a dividend yield reduces its appeal to certain investors.

Positive Factors

Sustained revenue and margin improvement

Consistent revenue growth alongside improved net margins signals durable demand across products and better cost control. Over a 2-6 month horizon this supports reinvestment ability, strengthens earnings resiliency, and underpins longer-term cash generation assuming current trends continue.

Solid balance sheet and moderate leverage

A strong equity base and moderate leverage provide financial flexibility to fund working capital, capex or expansions without excessive refinancing risk. This capital structure supports stability through industry cycles and allows strategic investment over the coming months.

Diverse pharma business model

A mix of domestic formulations, exports and contract manufacturing diversifies revenue and reduces dependence on a single channel. This multi-stream model supports steadier utilization, repeat contract revenue, and export market exposure that can sustain growth and margins over time.

Negative Factors

Weak free cash flow

Negative free cash flow from higher capex undermines the company’s ability to self-fund operations or growth without external financing. Over several months this can constrain strategic flexibility, delay deleveraging or require higher working capital management focus to restore cash conversion.

Operational efficiency headroom

Moderate operating margins indicate limited operating leverage and sensitivity to cost pressures. Unless efficiency initiatives raise EBIT/EBITDA, margin compression from input costs or pricing pressure could reduce sustainable profitability and limit free cash generation over the medium term.

Underutilized assets

Notable scope to improve asset utilization implies current ROA and capital efficiency are suboptimal. Persistently low turnover of assets can cap return on equity and growth ROI, requiring management action to boost volumes, realize capacity or divest non-core assets to improve long-term returns.

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

How the Company Makes Money

Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical products and related services through a mix of (1) domestic sales of finished formulations to distributors, hospitals, institutions, and other pharma trade channels, and (2) export sales of finished formulations to international customers (including distributors and marketing partners in overseas markets). A key revenue stream is manufacturing-based: it earns revenue from producing and supplying finished dosage forms under its own portfolio and/or for other companies under contract/third-party manufacturing arrangements, where revenue is generated either from product supply (per unit/lot) or agreed manufacturing terms. The company’s earnings are influenced by product mix (which molecules/dosage forms sell), geographic mix (domestic vs. export), regulatory compliance and approvals for target markets, customer concentration (repeat orders from key distributors/partners), and pricing/volume dynamics in the generics/formulations market. Specific material partnerships, product-wise revenue breakdowns, or segment-wise contribution figures are null.

Kilitch Drugs (India) Limited Financial Statement Overview

Summary

Kilitch Drugs shows strong revenue growth and improved profit margins, indicating sound financial health. However, operational efficiency and cash flow conversion need improvement, as evidenced by moderate EBIT and EBITDA margins and challenges in free cash flow.

Income Statement

Kilitch Drugs has demonstrated robust revenue growth with a notable increase in total revenue from previous years. The gross profit margin is healthy, indicating effective cost management. Net profit margin has improved significantly, showcasing enhanced profitability. However, the EBIT and EBITDA margins, although positive, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong equity position with a favorable equity ratio. The debt-to-equity ratio is moderate, suggesting a balanced approach to leverage. Return on Equity (ROE) indicates a positive return on shareholder investments, although it could be further optimized. Overall, the balance sheet is stable but has potential for better utilization of assets.

Cash Flow

The cash flow statement shows challenges in free cash flow, with negative growth in recent periods due to increased capital expenditures. The operating cash flow to net income ratio is positive but indicates that the company is facing difficulties in translating earnings into cash flow. Improvements in cash management could enhance financial flexibility.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.09B	1.98B	1.54B	1.40B	1.14B	681.28M
Gross Profit	951.14M	937.39M	731.38M	624.64M	337.44M	300.07M
EBITDA	446.60M	426.26M	287.43M	206.50M	134.13M	79.85M
Net Income	275.76M	267.01M	146.01M	104.48M	73.67M	36.71M
Balance Sheet
Total Assets	3.99B	3.13B	2.40B	2.20B	2.10B	2.03B
Cash, Cash Equivalents and Short-Term Investments	870.13M	593.98M	690.19M	591.77M	572.43M	488.49M
Total Debt	836.13M	494.24M	316.46M	221.94M	204.32M	148.04M
Total Liabilities	1.34B	1.12B	643.88M	689.41M	695.55M	736.97M
Stockholders Equity	2.66B	2.02B	1.76B	1.52B	1.39B	1.27B
Cash Flow
Free Cash Flow	-581.23M	-293.31M	-65.97M	-12.26M	-24.19M	93.61M
Operating Cash Flow	-66.20M	175.42M	-1.46M	25.86M	57.83M	456.59M
Investing Cash Flow	-514.49M	-399.47M	-95.45M	79.15M	-152.50M	-375.69M
Financing Cash Flow	813.60M	132.43M	88.07M	-7.16M	70.28M	16.14M

Kilitch Drugs (India) Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 355.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Negative. The current price of 355.6 is above the 20-day moving average (MA) of 319.58, above the 50-day MA of 329.02, and below the 200-day MA of 373.25, indicating a bearish trend. The MACD of -3.90 indicates Negative momentum. The RSI at 44.75 is Neutral, neither overbought nor oversold. The STOCH value of 59.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹11.59B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹11.66B	22.21	―	―	24.20%	55.01%
INDSWFTLAB	61 Neutral	₹11.57B	18.86	―	―	-37.70%	-19.79%
KILITCH	57 Neutral	₹5.51B	34.53	―	―	32.95%	67.39%
MEDICAMEQ	55 Neutral	₹3.41B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹2.45B	7.63	―	―	-30.27%	-3470.06%